For half a century, Grand Shuyang has continuously innovated and developed in the field of blood (plasma-derived) products, becoming one of China’s leading high-tech enterprises in this industry. It focuses on both domestic and global markets and boasts a modern production base that integrates automation and information technology, covering the entire product chain and ranking among the top in China in terms of production capacity. Grand Shuyang continuously expands its Plasma-derived product pipeline, including Human Albumin · Human Immunoglobulin (pH4) Intravenous injection · Hepatitis B Human Immunoglobulin (pH4) Intravenous injection· Hepatitis B Human Immunoglobulin ...

external link